Stephens Consulting’s Biogen BIIB Stock Holding History

Stephens Consulting’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4	Closed	-$503	–	486
2025 Q2	$503	Buy	+4	New	+$498	﹤0.01%	902
2022 Q1	–	Sell	-165	Closed	-$39.6K	–	573
2021 Q4	$39.6K	Buy	+165	New	+$42.4K	0.03%	226

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Stephens Consulting's BIIB Position: Q3 2025 in Review

Stephens Consulting sold out of Biogen (BIIB) in Q3 2025, closing a stake of 4 shares — an estimated $503 sold.

Stephens Consulting first reported a position in BIIB in Q4 2021 and held it in 2 quarters. The position peaked at $39.6K in Q4 2021. 907 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

Stephens Consulting reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
Stephens Consulting sold 4 Biogen shares in Q3 2025, an estimated $503.
Stephens Consulting first reported a position in Biogen in Q4 2021 and held it in 2 quarters.
Stephens Consulting's Biogen position peaked at $39.6K in Q4 2021.
907 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.